Page 62 - Read Online
P. 62

Page 16 of 18                              Galicia-Moreno et al. Hepatoma Res 2020;6:20  I  http://dx.doi.org/10.20517/2394-5079.2019.36


                   2017;390:2627-42.
               29.  Méndez-Sánchez N, Villa AR, Chávez-Tapia NC, Ponciano-Rodriguez G, Almeda-Valdés P, et al. Trends in liver disease prevalence in
                   Mexico from 2005 to 2050 through mortality data. Ann Hepatol 2005;4:52-5.
               30.  Bailey MA, Brunt EM. Hepatocellular carcinoma: predisposing conditions and precursor lesions. Gastroenterol Clin North Am
                   2002:31:641-62.
               31.  Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, et al. Alpha-protein, des-gamma carboxyprothrombin, and lectin-bound alpha-
                   fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009;137:110-28.
               32.  El-Serag HB, Kramer JR, Chen GJ, Duan Z, Richardson PA, et al. Effectiveness of AFP and ultrasound tests on hepatocellular
                   carcinoma mortality in HCV-infected patients in the USA. GUT 2011;60:992-7.
               33.  Marrero JA. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment
                   Pharmacol Ther 2009;30:37-47.
               34.  European Association for the study of the liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical
                   practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.
               35.  Heimbach J, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, et al. AASLD guidelines for the treatment of hepatocellular carcinoma.
                   Hepatology 2018;67:358-80.
               36.  Marrero JA, Ahn J, Rajender Reddy K; American College of Gastroenterology. ACG clinical guideline: the diagnosis and management
                   of focal liver lesions. Am J Gastroenterol 2014;109:1328-47.
               37.  Kudo M, Matsui O, Izumi N, lijima H, Kadoya M, et al. JSH-consensus-based clinical practice guideline for the management of
                   hepatocellular carcinoma: 2014 update by the liver cancer study group of Japan. Liver Cancer 2014;3:458-68.
               38.  Matsui O. Analysis of intranodular hemodynamics of dysplastic nodules in cirrhotic livers. Radiology 2001;218:603-5.
               39.  Ueda K, Tereda T, Nakanuma Y, Matsui O. Vascular supply in adenomatous hyperplasia of the liver and hepatocellular carcinoma: a
                   morphometric study. Hum Pathol 1992;23:619-26.
               40.  Forner A, Vilana R, Ayuso C, Bianchi L, Solé M, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective
                   validation of the noninvasive diagnosis criteria for hepatocellular carcinoma. Hepatology 2008;47:97-104.
               41.  Sangiovanni A, Manini MA, Iavarone M, Romeo R, Forzenigo LV, et al. The diagnosis and economic impact of contrast imaging
                   techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010;59:638-44.
               42.  Bolondi L, Gaiani S, Celli N, Golfieri R, Grigioni WR, et al. Characterization of small nodules in cirrhosis by assessment of
                   vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 2005;42:27-34.
               43.  Hanna RF, Milousshev VZ, Tang A, Finklestone LA, Brejt SZ, et al. Comparative 13-year meta-analysis of the sensitivity and positive
                   predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdom Radiol 2016;41:71-90.
               44.  Lee YJ, Lee JM, Lee JS, Lee HY, Park BH, et al. Hepatocellular carcinoma: diagnosis performance of multidetector CT and MR
                   imaging a system review and meta-analysis. Radiology 2015;275:97-109.
               45.  Roberts LR, Sirlin CB, Zaiem F, Almasri J, Prokop LJ, et al. Imaging for the diagnosis of hepatocellular carcinoma: a systematic
                   review and meta-analysis. Hepatology 2018;67:401-21.
               46.  Kierans AS, Kang SK, Rosenkrantz AB. The diagnosis performance of dynamic contrast-enhanced MR imaging for detection of small
                   hepatocellular carcinoma measuring up to 2 cm: a meta-analysis. Radiology 2016;278:82-94.
               47.  Kele PG, Van der Jagt EJ. Diffusion weighted imaging in the liver. World J Gastroenterol 2010;16:1567-76.
               48.  Miller FH, Hammond N, Siddiqi AJ, Shroff S, Khatri G, et al. Utility of difussion-weighted MRI in distinguishing benign and
                   malignant hepatic lesion. J Magn Reson Imaging 2010;32:138-47.
               49.  Galea N, Cantisani V, Taouli B. Liver lesion detection and characterization: role of diffusion-weighted imaging. J Magn Reson
                   Imaging 2013;37:1260-76.
               50.  Van Beers BE, Pastor CM, Hussain HK. Primovist, Eovist: what to expect? J Hepatol 2012;57:421-9.
               51.  Caturelli E, Solmi L, Anti M, Fusilli S, Roselli P, et al. Ultrasound guided fine needle biopsy of early hepatocellular carcinoma
                   complicating liver cirrhosis: a multicentre study. Gut 2004;53:1356-62.
               52.  International Consensus Group for Hepatocellular Neoplasia, The International Consensus Group for Hepatocellular Neoplasia.
                   Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia.
                   Hepatology 2009;49:658-64.
               53.  Ponziani FR, Nicoletti A, Gasbarrini A, Pompili M. Diagnostic and therapeutic potential of the gut microbiota in patients with early
                   hepatocellular carcinoma. Ther Adv Med Oncol 2019;11;1758835919848184.
               54.  Kawai T, Akira S. The roles of TLRs, RLSs and NLRs in pathogen recognition. Int Immunol 2009;21:317-37.
               55.  Miao EA, Andersen-Nissen E, Warren SE, Aderem A. TLR5 and Ipaf: dual sensors of bacterial flagellin in the innate immune system.
                   Semin Immunopathol 2007;29:275-88.
               56.  Luedde T, Schwabe RF. NF-kB in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol
                   2011;8:108-28.
               57.  Jung IH, Choi JH, Chung YY, Lim GL, Park YN, et al. Predominant acivation of JAK/STAT3 pathway by interleukin-6 is implicated
                   in hepatocarcinogenesis. Neoplasia 2015;17:586-697.
               58.  Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67
                   subtypes: updatecrietria and genotype assignment web resource. Hepatology 2013;59:318-27.
               59.  Arca-Lafuente S, Martínez-Román P, Mateo-Cano I, Madrid R, Briz V. Nanotechnology: a reality for diagnosis of HCV infectious
                   disease. J Infect 2019;30:30281-6.
               60.  Hussain MM, Samir TM, Azzazy HME. Unmodified gold nanoparticles for direct and rapid detection of mycobacterium tuberculosis
                   complex. Clin Biochem 2013;46:633-7.
               61.  Gill P, Alvandi A, Abdul-tehrani H, Sadeghizadeh M. Colorimetric detection of helicobacter pylori DNA using isothermal helicase-
   57   58   59   60   61   62   63   64   65   66   67